SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (10205)9/9/2009 2:40:34 PM
From: scaram(o)uche  Respond to of 10345
 
>> since she is about to start my wife on the drug through a compounding pharmacy <<

nice.... thanks for the update.... good news!



To: IRWIN JAMES FRANKEL who wrote (10205)9/9/2009 5:31:41 PM
From: DewDiligence_on_SI1 Recommendation  Respond to of 10345
 
>1 in 1,200 may overstate the risk. That formulation of the risk totally ignores the risk of untreated or inadequately treated MS.<

???

The stated figure in the WSJ article is the cumulative 3-year risk of PML, specifically. The risk of under-treatment of the underlying disease is relevant, of course, but it does not change the PML arithmetic at all.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News